A surprise clinical trial failure from Bristol-Myers Squibb is the latest evidence that drug development is inherently risky. Bristol-Myers shares plunged about 16% early Friday after it announced a failed clinical trial for one of the most promising cancer drugs on the... It should also remind investors of the importance of a clean balance sheet.

Source: Wall Street Journal August 05, 2016 14:46 UTC